Revolution Medicines (RVMD) CFO Jack Anders Sells $3.4M of Stock

Inside the Recent Insider Trades at Revolution Medicines

Chief Financial Officer Jack Anders parted with 20,000 shares of Revolution Medicines, Inc. (NasdaqGS:RVMD) on June 24, 2026. The transaction took place at an average price of $168.33 per share, leading to a total value of approximately $3.37 million. This move followed an earlier transaction on June 16, 2026, when Anders disposed of 2,722 shares at $156.12 each for a total of $424,958.64. Both of these recent sales were executed through a pre-arranged trading plan.

Other key leaders at the biotechnology firm have also adjusted their holdings recently. On June 16, 2026, President and Chief Executive Officer Mark Goldsmith sold 10,020 shares at $156.12 per share, totaling about $1.56 million under a pre-arranged schedule. Meanwhile, mid-June saw open-market buying activity from other insiders. On June 18, 2026, Sushil Patel picked up 3,127 shares, Flavia Borellini acquired 1,191 shares, and Lorence Kim bought 3,127 shares.

Where RVMD Stock Stands Today

Shares of Revolution Medicines trade around $182.08. The company is a clinical-stage precision oncology firm focused on targeted therapies for RAS-addicted cancers. Wall Street sentiment remains optimistic as the company moves its pipeline forward.

Wall Street Analyst Outlook

Wall Street firms maintain an upbeat view on the company's trajectory. On October 16, 2026, William Blair initiated coverage on the stock with an Outperform rating. Just a day prior, Needham reiterated its Buy rating alongside a $275.00 price target. RBC Capital also adjusted its outlook, maintaining an Outperform rating while lifting its target to $260.00 on October 14, 2026, following an earlier bump to $259.00 on October 8, 2026. Truist Securities kept a Buy rating with a $240.00 target on October 7, 2026. Brookline Capital initiated a Buy rating with a $318.00 target on September 28, 2026. B of A Securities maintained a Buy rating and raised its target to $265.00 on September 21, 2026, while Morgan Stanley initiated coverage with an Overweight rating and a $255.00 target on September 10, 2026. Overall, the stock carries a strong buy consensus recommendation from twenty analysts, with a mean price target of $253.21.

Inside Revolution Medicines' Oncology Pipeline

Headquartered in Redwood City, California, Revolution Medicines develops advanced precision medicines for cancers driven by RAS mutations. Its research pipeline centers on RAS(ON) inhibitors and companion inhibitors designed to tackle difficult tumors. Key candidates include daraxonrasib and elironrasib, which target specific solid tumors and are advancing through various clinical development stages.

Looking Ahead for Shareholders

Investors will be tracking upcoming corporate updates and the next scheduled financial results release on November 4, 2020. Market participants continue to watch how leadership balances pre-arranged stock sales with the ongoing clinical progress of the company's oncology pipeline.